» Articles » PMID: 23200854

Epistasis Between MicroRNAs 155 and 146a During T Cell-mediated Antitumor Immunity

Overview
Journal Cell Rep
Publisher Cell Press
Date 2012 Dec 4
PMID 23200854
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

An increased understanding of antitumor immunity is necessary for improving cell-based immunotherapies against human cancers. Here, we investigated the roles of two immune system-expressed microRNAs (miRNAs), miR-155 and miR-146a, in the regulation of antitumor immune responses. Our results indicate that miR-155 promotes and miR-146a inhibits interferon γ (IFNγ) responses by T cells and reduces solid tumor growth in vivo. Using a double-knockout (DKO) mouse strain deficient in both miR-155 and miR-146a, we have also identified an epistatic relationship between these two miRNAs. DKO mice had defective T cell responses and tumor growth phenotypes similar to miR-155(-/-) mice. Further analysis of the T cell compartment revealed that miR-155 modulates IFNγ expression through a mechanism involving repression of Ship1. Our work reveals critical roles for miRNAs in the reciprocal regulation of CD4(+) and CD8(+) T cell-mediated antitumor immunity and demonstrates the dominant nature of miR-155 during its promotion of immune responses.

Citing Articles

Non-coding RNA Networks in Infection.

Janga H, Schmerer N, Aznaourova M, Schulte L Methods Mol Biol. 2024; 2883:53-77.

PMID: 39702704 DOI: 10.1007/978-1-0716-4290-0_3.


MiRNAs as Regulators of Immune Cells in the Tumor Microenvironment of Ovarian Cancer.

Wilczynski M, Wilczynski J, Nowak M Cells. 2024; 13(16.

PMID: 39195233 PMC: 11352322. DOI: 10.3390/cells13161343.


Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy.

Li K, Wang J, Xie Y, Lu Z, Sun W, Wang K J Nanobiotechnology. 2024; 22(1):400.

PMID: 38972995 PMC: 11229347. DOI: 10.1186/s12951-024-02575-5.


Functionalized nanowires for miRNA-mediated therapeutic programming of naïve T cells.

Yee Mon K, Kim S, Dai Z, West J, Zhu H, Jain R Nat Nanotechnol. 2024; 19(8):1190-1202.

PMID: 38684809 PMC: 11330359. DOI: 10.1038/s41565-024-01649-7.


miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review.

Garcia-Gimenez J, Saadi W, Ortega A, Lahoz A, Suay G, Carretero J Int J Mol Sci. 2024; 25(3).

PMID: 38339019 PMC: 10855819. DOI: 10.3390/ijms25031737.


References
1.
Lu L, Boldin M, Chaudhry A, Lin L, Taganov K, Hanada T . Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010; 142(6):914-29. PMC: 3049116. DOI: 10.1016/j.cell.2010.08.012. View

2.
Zhao J, Rao D, Boldin M, Taganov K, OConnell R, Baltimore D . NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A. 2011; 108(22):9184-9. PMC: 3107319. DOI: 10.1073/pnas.1105398108. View

3.
Segura M, Belitskaya-Levy I, Rose A, Zakrzewski J, Gaziel A, Hanniford D . Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res. 2010; 16(5):1577-86. PMC: 4662869. DOI: 10.1158/1078-0432.CCR-09-2721. View

4.
Zheng S, Guo G, Zhang W, Huang G, Hu X, Zhu J . Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol Rep. 2012; 27(4):1149-55. PMC: 3583512. DOI: 10.3892/or.2012.1634. View

5.
Maekawa R, Kitagawa T, Hojo K, Wada T, Sato K . Distinct antitumor mechanisms of recombinant murine interferon-gamma against two murine tumor models. J Interferon Res. 1988; 8(2):227-39. DOI: 10.1089/jir.1988.8.227. View